Sanofi announces buy back of shares from L’Oréal

Sanofi kicks off share buyback plan with $3bn L’Oréal stake purchase
L'Oréal is selling nearly 30 million shares in Sanofi, decreasing its stake in the drugmaker from 9.4% to 7.2%.
Sanofi Buys Back Shares From L’Oréal
PARIS – L’Oréal has agreed to sell about 29.6 million Sanofi shares to Sanofi for approximately 3 billion euros.
Press Release: Sanofi announces buy back of shares from L’Oréal
Sanofi announces buy back of shares from L’OréalParis, February 3, 2025. Sanofi today announces the acquisition of 2.3% of its shares from
Sanofi Buys Back ~$3 Billion In Shares From L'Oréal: Details
Sanofi has purchased 2.3% of its shares from L'Oréal SA as part of its share repurchase program. The €3 billion deal involves acquiring 29.6 million shares at €101.50 each, with cancellation expected by April 29,
French pharma Sanofi to repurchase L'Oréal shares
French pharmaceutical company Sanofi said on Monday that it plans to buy back shares from cosmetics firm L'Oréal. Sanofi said the acquisition would be of 2.3% of its shares from L'Oréal. This transaction is part of a share buyback programme announced on January 30,
Sanofi Announces Buy Back Of Shares From L'Oréal - Quick Facts
Sanofi announced the acquisition of 2.3% of its shares from L'Oréal. This transaction is part of share buyback program announced on
FiercePharma3h
Regeneron tangles with Sanofi over commercial transparency in long-running Dupixent collaboration
Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...
L’Oreal to Sell $3.1 Billion Stake in Sanofi Back to Pharma Group
The deal will diversify the French beauty giant’s funding sources at a time when the industry is undergoing a slowdown.
policymed.com2d
Sanofi Sues HHS Over 340B Changes
Sanofi-Aventis US LLC filed a lawsuit against the Department of Health and Human Services (HHS) and the Health Resources and ...
FiercePharma7d
Sanofi's RSV antibody Beyfortus, after smashing blockbuster sales threshold, still has room to grow in US: execs
While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...
FierceBiotech3d
Sanofi-backed AdvanCell secures $112M series C to fund targeted alpha radiopharma trial
AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company ...
Sanofi Expected to Report Lower Sales, Profit; Size of Buyback in Focus -- Earnings Preview
BUSINESS OPERATING PROFIT FORECAST: Business operating profit--one of the company's preferred metrics, which strips out exceptional items--is forecast at 2.08 billion euros, according to the Vara ...
American Association of Individual Investors6d
Which Is a Better Investment, Sanofi or Zoetis Inc. Stock?
Learn more about whether Sanofi or Zoetis Inc. is a better investment based on AAII's A+ Investor grades, which compare both ...
Sanofi stock price target raised to EUR6.50 by CFRA
CFRA analysts increased their price target on shares of Sanofi (SAN:FP) (NASDAQ: NASDAQ:SNY) to EUR6.50, up from the previous EUR5.00, while keeping a Buy rating on the stock. Currently trading at $54 ...